Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bharat Biotech Justifies Trial Site Shifts For Tetravalent Vaccine

Executive Summary

Trial-related challenges in India appear to have pushed vaccine maker Bharat Biotech towards opting for alternative sites for studies on its tetravalent vaccine. The firm says it has justified its position to the regulator, though some experts advise diligence in site selection.

You may also be interested in...



Bharat Biotech Gets WHO Nod For ‘Game-Changer’ Typhoid Vaccine

India’s Bharat Biotech has won WHO pre-qualification for a vaccine against typhoid fever that experts say will be a “game-changer” in preventing the bacterial disease, especially among children under two years - the age group most at risk.

Serum Leads Way With Heat-Stable Rotavirus Vaccine But Competition Unfazed

Serum Institute has launched a cut-price oral thermostable rotavirus vaccine in India, but competitors like Hilleman Labs, also developing a heat-stable vaccine in the area, aren’t losing much sleep, for now at least. Serum has also introduced a rabies monoclonal antibody.

Pfizer Upjohn’s Ray On Changing The Grave Trajectory Of NCDs

Pfizer Upjohn’s Global President of R&D and Medical, Amrit Ray, talks in a wide-ranging interview about the need for tailored interventions to address the growing burden of non-communicable diseases and efforts around harnessing real world data. He also underscores the importance of investing in primary care and a primary health workforce against the backdrop of outbreaks such as coronavirus.

Topics

Related Companies

UsernamePublicRestriction

Register

PS123381

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel